AlphaCore Capital LLC Makes New $793,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

AlphaCore Capital LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 8,815 shares of the medical equipment provider’s stock, valued at approximately $793,000.

Several other hedge funds also recently bought and sold shares of ZBH. Cullen Frost Bankers Inc. raised its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. TD Private Client Wealth LLC raised its holdings in shares of Zimmer Biomet by 14.0% during the third quarter. TD Private Client Wealth LLC now owns 999 shares of the medical equipment provider’s stock worth $98,000 after acquiring an additional 123 shares during the period. Boltwood Capital Management raised its holdings in shares of Zimmer Biomet by 3.9% during the fourth quarter. Boltwood Capital Management now owns 3,866 shares of the medical equipment provider’s stock worth $348,000 after acquiring an additional 144 shares during the period. Independence Bank of Kentucky raised its holdings in shares of Zimmer Biomet by 9.7% during the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock worth $147,000 after acquiring an additional 145 shares during the period. Finally, LOM Asset Management Ltd raised its holdings in shares of Zimmer Biomet by 21.5% during the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after acquiring an additional 147 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at $967,803.84. The trade was a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.28% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Up 1.7%

Shares of ZBH opened at $85.09 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $108.29. The firm has a market cap of $16.46 billion, a P/E ratio of 22.10, a price-to-earnings-growth ratio of 1.94 and a beta of 0.48. The firm’s 50-day simple moving average is $89.43 and its 200 day simple moving average is $91.32. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter in the prior year, the business earned $1.81 EPS. Zimmer Biomet’s quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were issued a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is currently 24.94%.

Analyst Ratings Changes

A number of equities research analysts recently commented on ZBH shares. Robert W. Baird set a $92.00 price objective on shares of Zimmer Biomet in a report on Wednesday, April 29th. Stifel Nicolaus cut their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Barclays cut their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a research report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $102.80.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.